Newsbenzinga
First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…